Provectus Biopharmaceuticals Retains PharmaHEALTHLabs to Facilitate Investigator Advisory Board Meeting During 11Th Brazilian...
June 22 2015 - 6:00AM
Business Wire
Briefing for Approximately 15 Brazilian
Melanoma Specialists in Goiania, Brazil
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,
http://www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company (“Provectus” or the “Company”), announced
that it has retained healthcare communications company
PharmaHEALTHLabs to coordinate and facilitate an Investigator
Advisory Board meeting to be held during 11th Brazilian Melanoma
Conference from August 13-15, 2015 in Goiania, Brazil.
The meeting will target approximately 15 key oncologists who
will be attending the conference and who are active in the
investigator community in Brazil for the treatment of melanoma. The
purpose is to offer insight and feedback into the status of
treatment of melanoma in Brazil as well as the feasibility of
initiating the PV-10 Trial in Brazil.
Under the terms of the agreement, PharmaHEALTHLabs will provide
a dedicated management team to handle numerous functions at which
their company excels. This includes, but is not limited to, content
development; overall account and project management; participant
recruitment, planning and contracting; expense accounting
functions; development of meeting materials; venue research and
contracting; program coordination and logistics; travel and
accommodations; onsite support; and meeting summary and
reporting.
Peter Culpepper, CFO and COO, of Provectus said, “The 11th
Brazilian Melanoma Conference is a gathering of melanoma experts
from all around Brazil, a country where melanoma survival rates are
lower than average, that offers us a unique opportunity to explore
the possibilities of extending our melanoma research into Brazil.
PharmaHEALTHLabs’ personnel are highly experienced in melanoma and
in managing the kind of meeting we need to have with the leading
investigators in the country, and we are confident that their
efforts will help us quickly and clearly understand the potential
of Brazil in our PV-10 development program.”
Jeff Meehan, PharmaHEALTHLabs Lead Oncology Advisor, said,
“PharmaHEALTHLabs is very happy to be working with Provectus in
assessing the potential of Brazil as a place for further research
into PV-10 in melanoma. Putting together this kind of high level
meeting on an international level requires agility as well as
experience, and we believe that Provectus will be highly pleased
with the quality of the information they receive.”
About PharmaHEALTHLabs
PharmaHEALTHLabs is a healthcare communications company based in
Morristown, NJ that creates compelling solutions for life sciences
companies.
PharmaHEALTHLabs combines insightful strategy, award-winning
creative, and high impact editorial with practical know-how,
ensuring each project is not only compelling and engaging, but also
simple to understand and communicate. We are nimble, agile, and
cutting edge. We treat every customer and every project with
respect and personalization. We provide teams dedicated to a
client’s business so there is a consistent point of contact that
can continue to build on learnings over time. We strive to give our
clients the best experience possible when dealing with a solutions
agency.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company’s other
clinical trials, including its current phase 3 study in melanoma,
can be found at the NIH registry, www.clinicaltrials.gov. For
additional information about Provectus, please visit the Company’s
website at www.pvct.com or contact Porter, LeVay & Rose,
Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2014) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our melanoma drug product candidate, and other solid tumors
such as cancers of the liver, if such licensure is appropriate
considering the timing and structure of such a license, or to
commercialize PV-10 on our own to treat melanoma and other solid
tumors such as cancers of the liver;
- our ability to license our dermatology
drug product candidate, PH-10, on the basis of our phase 2 atopic
dermatitis and psoriasis results, which are in the process of being
further developed in conjunction with mechanism of action studies;
and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150622005247/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO,
COO866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse,
DM, SVP – Investor Relations212-564-4700orTodd Aydelotte – Media
Relations646-428-0644
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024